Diabetic neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical concepts, mechanisms, and treatment
PubMed 22810070 · doi:10.1212/01.CON.0000411568.34085.3e
What was done
This narrative review summarizes the classification, pathophysiological mechanisms, diagnosis, and treatment approaches for various forms of diabetic peripheral neuropathy.
What was found
The abstract reports that diabetes is the leading cause of peripheral neuropathy worldwide, affecting more than half of patients with diabetes and accounting for half of all neuropathy cases. The review categorizes presentations into chronic forms (primarily distal symmetric polyneuropathy) and acute forms (such as diabetic amyotrophy and treatment-related neuropathy/insulin neuritis). Emerging literature highlights contributions from prediabetic hyperglycemia, obesity, and dyslipidemia to neuropathy risk, alongside inflammatory mechanisms in acute neuropathies, while disease-modifying therapies remain elusive.
Why it matters
It provides a clinical framework for distinguishing chronic metabolic neuropathies from acute, potentially inflammatory diabetic neuropathies, highlighting the broader role of metabolic syndrome factors in nerve damage.
Limits
The abstract provides general epidemiologic estimates without specific study citations, quantitative effect sizes, or a systematic search methodology.
Cited by
- supports Diabetes is the leading cause of peripheral neuropathy in the United States.